All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 1 February 2019, Anas Younes from Memorial Sloan Kettering Cancer Center, New York, NY, USA and colleagues, published in The Lancet Haematology a phase 1-2a study investigating the safety of ibrutinib in combination with nivolumab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.
In this two-part, multicenter, open label, phase 1-2a study the appropriate dose (phase 1), as well as the safety and activity (phase 2a) of ibrutinib in combination with nivolumab were assessed in the following patient populations: R/R CLL/SLL with del17p or del11q (high-risk), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), or Richter’s transformation (RT). The primary aim of the phase 1 part of the study was to establish the appropriate treatment dose. The primary endpoint of the phase 2a part was to measure the preliminary efficacy of ibrutinib and nivolumab in the aforementioned patient populations, by assessing the proportion of patients achieving an overall response.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox